Putting the Patient First: Advancing Biopharma Innovation and Industry Transformation

Norstella is driven by its mission: Helping patients gain access to life-saving therapies by transforming the drug development journey. Norstella is working to fulfill this mission in a challenging landscape for pharmaceutical, medtech, and clinical research organizations. With this as the context, Norstella recently held a recent roundtable discussion in London featuring several members of […]
Obesity R&D in 2024 & Beyond: Key Considerations in an Increasingly Competitive Landscape

Norstella empowers stakeholders involved in obesity drug development to make informed decisions based on trusted industry data and expert insights. This infographic uses some of those data and insights to demonstrate the various complex factors that continue to impact obesity R&D, assess expectations for future development in this space, and emphasize how Norstella serves as […]
Unlocking Success in the Evolving Pharma Landscape: Insights from Norstella’s Daniel Chancellor

Recent breakthroughs in obesity, Alzheimer’s, and other major disease areas are reshaping pharma R&D priorities and forcing companies to rethink pipeline strategy, payer value communication, and long-term growth. The discussion highlights the importance of learning from both drug development successes and failures, while emphasizing emerging opportunities in areas like cell, gene, and RNA therapies, as […]
Paving the Way for Women in Life Sciences

The ultimate success of the life sciences industry is highly dependent on a diverse workforce of pioneers, collaborators, and change-drivers, though there is still progress to be made with regard to gender equality in this field. Life sciences organizations are thus exploring ways to best prioritize diversity, including how to advocate for equality among leadership […]
How Real-World Evidence is Impacting Regulatory Decision-Making: A Collection of 10 Recent Regulatory Decisions Based on RWE

Volume 3 Discover the power of real-world evidence (RWE) in shaping regulatory decisions through “How RWE is Impacting Regulatory Decision-Making.” Volume 3 of Panalgo’s popular use cases series reveals 10 recent instances where life sciences companies have not only invested in RWE but have successfully utilized it in their submissions to the FDA and other […]
How Real-World Evidence is Impacting Regulatory Decision-Making: 12 Recent Approvals Based on RWE

Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE.
How Real-World Evidence is Impacting Regulatory Decision-Making: A Collection of 12 Recent Approvals Based on RWE

Volume 1 From the new FDA framework to the urgency of COVID-19, recent events have dramatically accelerated the use of RWE in regulatory decision-making. Now, life sciences organizations are investing heavily in analytics to generate RWE for regulatory submission.